Introduction
============

Polycystic ovary syndrome (PCOS) is a life-long endocrinopathy which affects approximately 10% of women in the reproductive age.[@b1-tcrm-11-1345]--[@b3-tcrm-11-1345] Although its pathogenesis has not been clearly identified, genetics and lifestyle factors may cause the development of the major features of PCOS.[@b4-tcrm-11-1345] Women with PCOS present with the following symptoms: ovulatory dysfunction, hyperandrogenism, and polycystic ovaries; however, variation in presentation exists between PCOS patients.[@b1-tcrm-11-1345],[@b3-tcrm-11-1345] Although obesity, insulin resistance, and hyperinsulinemia are not required for the diagnosis of PCOS ([Table 1](#t1-tcrm-11-1345){ref-type="table"}), they commonly occur in women with PCOS, increasing susceptibility to metabolic complications such as type 2 diabetes, hyperlipidemia, hypertension, fatty liver, and sleep apnea.[@b3-tcrm-11-1345]--[@b8-tcrm-11-1345] Consequently, PCOS causes endocrine, metabolic, and cardiovascular symptoms in affected women.

Women with PCOS usually seek treatment to manage the androgen-related symptoms, menstrual-related disorders, and infertility.[@b3-tcrm-11-1345],[@b4-tcrm-11-1345],[@b8-tcrm-11-1345] However, they also have various long-term complications which have been frequently underestimated.[@b9-tcrm-11-1345] For instance, gestational diabetes and hypertensive disorders are more likely to occur in women with PCOS during pregnancy, and as they get older, metabolic diseases including glucose intolerance, type 2 diabetes, or hyperlipidemia are frequently observed.[@b9-tcrm-11-1345] Therefore, lifelong follow-up and management for these patients at risk are needed to detect and prevent complications as early as possible.

The major treatment modalities in PCOS are designed to control hyperandrogenism and lower insulin levels with improved insulin sensitivity, but the long-term treatment for PCOS is currently controversial.[@b10-tcrm-11-1345] The pharmacological agents commonly used in the treatment of PCOS include insulin sensitizers, oral contraceptive pills (OCPs), and antiandrogenic agents.[@b1-tcrm-11-1345],[@b11-tcrm-11-1345] The use of metformin, an insulin sensitizer, in women with PCOS resulted in the improvement of hyperinsulinemia, reduction of androgen levels, and improvement of menstrual irregularity.[@b12-tcrm-11-1345] Metformin treatment also positively affected lipid profiles in PCOS women.[@b13-tcrm-11-1345],[@b14-tcrm-11-1345] However, metformin treatment is associated with lactic acidosis, even though its incidence is rare, and may cause gastrointestinal side effects (SEs) such as nausea, which often disappear with long-term use.[@b1-tcrm-11-1345],[@b10-tcrm-11-1345]

OCPs may decrease androgen levels and increase sex hormone-binding globulins (SHBGs), which seems to impact positively the symptoms, such as hirsutism, acne, and alopecia, experienced by women with PCOS.[@b15-tcrm-11-1345] It is also likely that OCPs have a positive effect on low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and total cholesterol, except for triglycerides.[@b15-tcrm-11-1345] On the other hand, weight gain, cardiovascular, and thromboembolic events can occur with the use of OCPs.[@b1-tcrm-11-1345],[@b16-tcrm-11-1345]--[@b18-tcrm-11-1345] Therefore, it is important to consider the efficacy and safety of metformin and OPSs, to appropriately treat the symptoms that occur in women with PCOS.

The aims of this review were to report the efficacy and safety of metformin, OCPs, or the combination of both of these agents in the treatment of women with PCOS. In addition, we sought to define the roles of metformin and OCPs in the treatment of the symptoms that women with PCOS may experience.

Methods
=======

A literature search was performed to identify clinical trials in women with PCOS, which evaluated the efficacy and safety of metformin, OCPs, or a combination of both agents. PubMed and Scopus were searched to find the clinical trials written only in English. The following search terms were used: metformin, contraceptives, and polycystic ovary syndrome. The reference lists of the selected articles and related reviews were used to identify additional articles. Two reviewers independently scanned the article titles and abstracts and identified relevant studies that may fulfill the following inclusion criteria: 1) only prospective studies were eligible, 2) reproductive-aged women with PCOS, 3) metformin or OCPs had to be used for the treatment of PCOS, and 4) end points must contain endocrine and metabolic parameters.

Results
=======

On the basis of the literature search ([Figure 1](#f1-tcrm-11-1345){ref-type="fig"}), eight eligible clinical trials were identified that met the inclusion criteria, and the relevant findings from the selected trials are presented in [Tables 2](#t2-tcrm-11-1345){ref-type="table"}[](#t3-tcrm-11-1345){ref-type="table"}--[4](#t4-tcrm-11-1345){ref-type="table"}.[@b10-tcrm-11-1345],[@b12-tcrm-11-1345],[@b14-tcrm-11-1345],[@b19-tcrm-11-1345]--[@b23-tcrm-11-1345] A total of 313 women with PCOS were enrolled in the trials. Approximately 81 women received metformin alone, 136 OCPs alone, and 96 the combination of metformin and OCP. The dose of metformin administered during the study periods ranged from 1,000 to 2,000 mg/d. The OCPs administered were mostly those containing ethinylestradiol 35 µg and cyproterone acetate 2 mg.

A total of 90 women fulfilling the Rotterdam criteria for PCOS were enrolled in the randomized, controlled clinical trial conducted by Glintborg et al[@b10-tcrm-11-1345] in Denmark. The patients received metformin (2,000 mg/d), OCP (desogestrel 150 mg plus ethinylestradiol 30 µg), and metformin with the OCP for 12 months. The body mass index (BMI) decreased in the groups administered metformin, whereas it increased in the OCP monotherapy group. The insulin level was reduced only in the patients who received metformin with OCP, and the total testosterone (T) levels were decreased in all the three groups. Although the SHBG levels were increased in all three groups, the highest increase was observed in the OCP monotherapy group. A total of 25 patients were withdrawn from the trial, and adverse effects observed included depression and nausea.

Another randomized, double-blind, placebo-controlled trial in USA enrolled 23 overweight women with PCOS as defined by the modified Rotterdam criteria.[@b19-tcrm-11-1345] The patients received either metformin (1,500 mg/d) with the OCP (ethinylestradiol 35 µg plus norgestimate 0.18/0.215/0.25 mg) or the OCP with a placebo for 3 months. The BMI was decreased by 1.9% in the metformin plus OCP group (*P*=0.006). The total cholesterol level was significantly increased in the OCP plus placebo group (*P*=0.03). The total T levels were decreased in both groups, but the extent of these changes was higher in the OCP plus placebo group than it was in the metformin plus OCP group. The SHBG level showed more improvement in the OCP plus placebo group than it did in the metformin plus OCP group (*P*=0.001). Four patients discontinued the trial, and one patient experienced heavy menstrual bleeding.

In the prospective randomized study conducted in Greece by Panidis et al,[@b20-tcrm-11-1345] 45 women with PCOS diagnosed in accordance with the NIH/National Institute of Child Health and Human Development criteria were divided into three groups: group A (ethinylestradiol 35 µg plus cyproterone acetate 2 mg), group B (ethinylestradiol 30 µg plus drospirenone 3 mg), and group C (metformin 1,700 mg/d). The treatments were continued for 6 months. The BMI was reduced by 5.6% in group C, and their insulin level was decreased by 0.93 µIU/mL. The total T levels were significantly decreased in both groups A (31.01 ng/dL, *P*=0.003) and B (27.55 ng/dL, *P*=0.006). Both groups A and B showed a significant increase in the SHBG levels (165.94 and 196.63 nmol/L, respectively, *P*\<0.001), while the SEs-related data were not reported.

A total of 40 women with PCOS, evaluated based on the Rotterdam criteria, were enrolled in the randomized clinical trial conducted by Bilgir et al[@b21-tcrm-11-1345] in Turkey. The patients received either metformin (1,700 mg/d) with an OCP (ethinylestradiol 35 µg plus cyproterone acetate 2 mg) or the OCP alone for 3 months. The BMI levels in the metformin plus OCP group and the OCP alone group were significantly decreased by 4.3% and 4.6% (*P*\<0.001), respectively. The lipid profiles were improved in both groups. Significant reductions in the insulin level were observed in the metformin plus OCP and OCP alone groups (3.2 and 2.4 µIU/mL, respectively, *P*\<0.001), while the related SEs were not reported.

In the prospective, open clinical study conducted in Bulgaria by Mitkov et al[@b14-tcrm-11-1345] 30 women with PCOS diagnosed based on the Rotterdam criteria received either metformin (1,700 mg/d) alone or metformin plus OCP (ethinylestradiol 35 µg plus cyproterone acetate 2 mg for the first 2 months) for 6 months. The BMI levels improved in both groups, but this was not statistically significant. The high-density lipoprotein levels increased in the metformin alone group, but decreased in the metformin plus OCP group. Both groups showed an improvement in the SHBG levels, but only the metforminalone group showed a significant increase (5.31 nmol/L, *P*\<0.05). No patients discontinued the trial, and no serious SEs were reported.

Approximately 20 nonobese (BMI \<25 kg/m^2^) women with PCOS as defined by Homburg[@b24-tcrm-11-1345] were randomized to either a metformin group (1,000 mg/d for 3 months, then 2,000 mg/d for 3 months) or OCP group (ethinylestradiol 35 µg plus cyproterone acetate 2 mg for 6 months) in the clinical trial conducted by Morin-Papunen et al[@b12-tcrm-11-1345] in Finland. The BMI levels improved in both groups, while a significant reduction (2.10 µIU/mL, *P*\<0.05) was observed in the insulin level of women in the metformin group. The total T levels were significantly decreased by 20.17 ng/dL (*P*\<0.05) in both the metformin and OCP groups. The OCP group also showed a significant increase (180.4 nmol/L, *P*\<0.001) in the SHBG level. Three patients discontinued the trial, and one patient experienced headache and high blood pressure.

A prospective, randomized study was conducted in Turkey by Elter et al involving 40 women who were nonobese (BMI \<25 kg/m^2^) with PCOS.[@b22-tcrm-11-1345] They were administered either metformin (1,000 mg/d for 15 days, and then 1,500 mg/d for the rest of study period) plus OCP (ethinylestradiol 35 µg plus cyproterone 2 mg) or the OCP alone for 6 months.[@b22-tcrm-11-1345] A significant reduction (0.54 kg/m^2^, *P*=0.003) was observed in the BMI level of the metformin plus OCP group. The absolute reduction in the insulin level was higher in the OCP group than it was in the metformin plus OCP group; however, the reduction (5.80 µIU/mL, *P*=0.001) was significant only in the metformin plus OCP group. A significant reduction was achieved in the total T levels of both the metformin plus OCP (32.56 ng/dL, *P*=0.032) and OCP (32.56 ng/dL, *P*=0.011) groups. The SHBG levels were also significantly increased in both the metformin plus OCP (59.71 nmol/L, *P*=0.001) and OCP (31.83 nmol/L, *P*=0.003) groups. No patients were withdrawn from the trial, and only minor SEs were reported.

A total of 25 women who were obese and had PCOS as defined by Homburg[@b24-tcrm-11-1345] were administered either metformin (1,000 mg/d for 3 months, then 2,000 mg/d for 3 months) or OCP (ethinylestradiol 35 µg plus cyproterone acetate 2 mg for 6 months) in the clinical trial conducted by Morin-Papunen et al[@b23-tcrm-11-1345] in Finland. The BMI and insulin levels were improved in both groups, but the insulin level of the metformin group was significantly more decreased (3.84 µIU/mL, *P*\<0.05). A significant reduction (31.70 ng/dL, *P*\<0.05) was observed in the total T level of the OCP group. The SHBG level was significantly decreased in the metformin group (5.4 nmol/L, *P*\<0.05), but significantly increased in the OCP group (130.1 nmol/L, *P*\<0.001). Seven patients discontinued the trial during the study period, while two patients experienced nausea, diarrhea, headache, and high blood pressure.

Discussion
==========

PCOS is a disease that occurs in approximately 10% of reproductive-aged women.[@b1-tcrm-11-1345]--[@b3-tcrm-11-1345] Women with PCOS experience endocrine, metabolic, and cardiovascular symptoms, such as ovulatory dysfunction, hyperandrogenism, polycystic ovaries, obesity, insulin resistance, and hyperinsulinemia.[@b1-tcrm-11-1345],[@b3-tcrm-11-1345],[@b4-tcrm-11-1345],[@b8-tcrm-11-1345] Traditionally, metformin or OCPs have been used to ameliorate the symptoms experienced by women with PCOS.[@b12-tcrm-11-1345]--[@b15-tcrm-11-1345] In this study, the efficacy and safety of metformin, OCPs, or a combination of both agents were determined using a literature search and analysis.

The clinical trials reviewed in this study demonstrated that metformin or OCPs have the potential to control the metabolic symptoms in women with PCOS. As shown in previous studies, the regimens that included metformin decreased the BMI levels.[@b25-tcrm-11-1345]--[@b28-tcrm-11-1345] However, in cases where only the OCPs were administered, their effects on the BMI levels were not clear. In some studies included in this review, the BMI levels were increased in women treated with only the OCPs, but the changes were not high.[@b10-tcrm-11-1345],[@b20-tcrm-11-1345],[@b22-tcrm-11-1345] Additionally, some studies reported changes in the lipid profiles; however, the effect of metformin or OCPs on the lipid profiles was not entirely clear.[@b14-tcrm-11-1345],[@b19-tcrm-11-1345],[@b21-tcrm-11-1345],[@b22-tcrm-11-1345] Metformin or OCPs, especially when only the OCPs were administered, did not consistently improve lipid profiles unlike the previous studies.[@b13-tcrm-11-1345]--[@b15-tcrm-11-1345] Different doses of metformin and combination of metformin and OCPs probably led to this result that metformin did not show an apparent association with an improvement in lipid profiles. Taken together, the data from the clinical trials evaluated in this study suggest that the use of metformin may be beneficial in managing metabolic symptoms experienced by women with PCOS. In contrast, the effect of the OCPs on the metabolic symptoms was hardly conclusive based on the data reviewed in this study.

In this study, the effect of metformin or OCPs on endocrine symptoms was assessed. There are still uncertainties about the effects of metformin or OCPs in controlling insulin levels. Statistically significant reductions were usually observed when metformin was administered, regardless of the specific regimens administered to the patients. However, unfortunately, not all the women with PCOS responded to metformin with improved insulin levels. In particular, it was reported in some studies that metformin did not affect insulin sensitivity without weight loss in women with PCOS.[@b29-tcrm-11-1345]--[@b31-tcrm-11-1345] Therefore, to optimize the beneficial effect of metformin on insulin levels, lifestyle modification interventions would also be necessary.[@b32-tcrm-11-1345] In cases where the OCP was administered as monotherapy, the insulin levels were decreased compared with the baseline levels, although the OCP monotherapy was shown to affect negatively the insulin levels in some studies.[@b10-tcrm-11-1345],[@b20-tcrm-11-1345] Additionally, metformin and OCPs improved the total T and SHBG levels.

Metformin does not usually cause significant SEs, but its use may be associated with a rare, but serious SE called lactic acidosis.[@b1-tcrm-11-1345],[@b10-tcrm-11-1345],[@b33-tcrm-11-1345]--[@b35-tcrm-11-1345] In the selected studies, gastrointestinal SEs such as nausea and diarrhea occurred in the patients administered metformin, which caused five patients to discontinue the trials. The use of OCPs can also cause SEs including weight gain as well as cardiovascular and thromboembolic events.[@b1-tcrm-11-1345],[@b16-tcrm-11-1345]--[@b18-tcrm-11-1345],[@b36-tcrm-11-1345],[@b37-tcrm-11-1345] Six patients who were administered OCPs discontinued the trials due to SEs such as headache, high blood pressure, and heavy menstrual bleeding. Although the total number of patients who discontinued the studies was small, the dropout rate of patients due to SEs could be relatively high when a small sample size is considered in each study. Long-term treatment of women with PCOS may be necessary because PCOS is a life-long endocrinopathy.[@b1-tcrm-11-1345]--[@b3-tcrm-11-1345] Therefore, it is likely that the incidence rate of the metformin- or OCPs-related SEs may be higher than observed in the included studies. In addition, adverse cardiovascular and metabolic effects, such as venous and arterial thrombosis, associated with OCPs vary among different formulations, and it is not possible to implement large randomized controlled trials to be enough for the detection of differences between various OCPs with respect to rare SEs like venous and arterial thrombosis.[@b38-tcrm-11-1345]

This study had a few limitations which have to be mentioned. We searched two electronic databases (ie, PubMed and Scopus) to identify relevant studies, although there are numerous databases available. This limited search could have also limited our chances of finding additional relevant studies. The eight selected studies used different types of OCPs and various treatment durations ranging from 3 to 12 months, which may lead to inconclusive results regarding OCPs' efficacy. Most of the selected studies in women with PCOS also focused on evaluating the efficacy of metformin or OCPs for the treatment of PCOS and very few analyzed the metformin- or OCPs-related SEs. In addition, most of the included studies were conducted for durations of less than 1 year; therefore, they did not observe SEs associated with metformin or OCPs because longer treatment durations are more often associated with higher incidences of SEs. Therefore, future long-term studies are necessary to determine the safety of metformin or OCPs in the treatment of PCOS. Lastly, the same PCOS diagnostic criteria were not applied in the evaluation of all the women with PCOS included in the selected studies. The disparate diagnosis may also have led to some of the vague results observed in the included studies.

Conclusion
==========

The clinical trials reviewed in this study suggest that metformin or OCPs can be at least efficacious and safe patient-convenient medications for the treatment of PCOS at this point. However, it is necessary to monitor PCOS women on these medications since rare SEs such as lactic acidosis or weight gain can occur by the long-term use of them. Further well-designed, prospective, long-term, large-scale, randomized clinical trials are also necessary to elucidate the efficacy and safety of metformin or OCPs in the treatment of women with PCOS and appropriately establish the role of these agents in the treatment of PCOS. In addition, studies regarding management strategies for PCOS patients in the prepubertal and postmenopausal periods are necessary in the near future.
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###### 

Diagnostic criteria for polycystic ovary syndrome

  NIH/NICHD, 1992[@b5-tcrm-11-1345]                                                                      ESHRE/ASRM (Rotterdam criteria), 2004[@b6-tcrm-11-1345]                                                                            Androgen excess society guideline, 2006[@b7-tcrm-11-1345]
  ------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------
  • Exclude other androgen excess or related disorders                                                   • Exclude other androgen excess or related disorders                                                                               • Exclude other androgen excess or related disorder
  • Include the following (clinical or biochemical hyperandrogenism or both and menstrual dysfunction)   • Include two of the following (clinical or biochemical hyperandrogenism or both; oligo- or anovulation; and polycystic ovaries)   • Include the following (clinical or biochemical hyperandrogenism or both and ovarian dysfunction, polycystic ovaries, or both)

**Abbreviations:** NIH/NICHD, National Institutes of Health/National Institute of Child Health and Human Disease; ESHRE/ASRM, European Society for Human Reproduction and Embryology/American Society for Reproductive medicine.

###### 

Study methods of selected clinical trials of metformin and oral contraceptive pills in treatment of polycystic ovary syndrome

  Trial                                    Intervention                                                                                                                                        Number of patients, n   Treatment duration, months   Mean age, years    Baseline mean BMI, kg/m^2^   Baseline mean insulin, µIU/mL   Baseline mean total T, ng/dL
  ---------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------- ---------------------------- ------------------ ---------------------------- ------------------------------- ------------------------------
  Glintborg et al[@b10-tcrm-11-1345]       M (2 g/d), M + OCP (150 mg desogestrel +30 µg ethinylestradiol), OCP                                                                                M: 30                   12                           M: 31              M: 25.9                      M: 7.34                         M: 56.48
  M + OCP: 30                              M + OCP: 30                                                                                                                                         M + OCP: 27.6           M + OCP: 6.77                M + OCP: 46.11                                                                  
  OCP: 30                                  OCP: 28                                                                                                                                             OCP: 28.0               OCP: 7.06                    OCP: 47.55                                                                      
  Essah et al[@b19-tcrm-11-1345]           M (500 mg TID) + OCP (ethinylestradiol 35 µg + norgestimate 0.18/0.215/0.25 mg), OCP + Pl                                                           M + OCP: 11             3                            NR                 M + OCP: 36.2                M + OCP: 9.82                   M + OCP: 340.06
  OCP + Pl: 12                                                                                                                                                                                 OCP + Pl: 32.6          OCP + Pl: 9.89               OCP + Pl: 377.52                                                                
  Panidis et al[@b20-tcrm-11-1345]         Group A (ethinylestradiol 35 µg + cyproterone acetate 2 mg), Group B (ethinylestradiol 30 µg + drospirenone 3 mg), Group C (metformin 850 mg BID)   Group A: 15             6                            Group A: 20.67     Group A: 21.04               Group A: 8.09                   Group A: 81.79
  Group B: 15                              Group B: 22.00                                                                                                                                      Group B: 21.69          Group B: 8.64                Group B: 83.14                                                                  
  Group C: 15                              Group C: 20.53                                                                                                                                      Group C: 21.83          Group C: 11.17               Group C: 84.15                                                                  
  Bilgir et al[@b21-tcrm-11-1345]          M (850 mg BID) + OCP (ethinylestradiol 35 µg + cyproterone acetate 2 mg), OCP                                                                       M + OCP: 20             3                            M + OCP: 25.2      M + OCP: 28.2                M + OCP: 20.1                   NR
  OCP: 20                                  OCP: 24.3                                                                                                                                           OCP: 28.2               OCP: 21.0                                                                                                    
  Mitkov et al[@b14-tcrm-11-1345]          M (850 mg BID), M + OCP (ethinylestradiol 35 µg + cyproterone acetate 2 mg during the first 2 months)                                               M: 15                   6                            Total: 23.8        M: 27.9                      M: 17.08                        M: 205.00
  M + OCP: 15                                                                                                                                                                                  M + OCP: 27.8           M + OCP: 15.13               M + OCP: 213.00                                                                 
  Morin-Papunen et al[@b12-tcrm-11-1345]   M (500 mg BID ×3 months, then 1,000 mg BID ×3 months), OCP (ethinylestradiol 35 µg + cyproterone acetate 2 mg)                                      M: 10                   6                            M: 28.2            M: 22.5                      M: 6.39                         M: 77.81
  OCP: 10                                  OCP: 28.5                                                                                                                                           OCP: 21.8               OCP: 8.22                    OCP: 60.52                                                                      
  Elter et al[@b22-tcrm-11-1345]           M (500 mg BID ×15 days, then 500 mg TID for the rest of the study period) + OCP (ethinylestradiol 35 µg + cyproterone 2 mg), OCP                    M + OCP: 20             4                            M + OCP: 24.90     M + OCP: 22.74               M + OCP: 17.58                  M + OCP: 78.39
  OCP: 20                                  OCP: 23.45                                                                                                                                          OCP: 21.83              OCP: 22.99                   OCP: 79.54                                                                      
  Morin-Papunen et al[@b23-tcrm-11-1345]   M (500 mg BID ×3 months, then 1,000 mg BID ×3 months), OCP (ethinylestradiol 35 µg + cyproterone acetate 2 mg)                                      M: 11                   6                            M: 29.9            M: 32.5                      M: 14.30                        NR
  OCP: 14                                  OCP: 29.8                                                                                                                                           OCP: 37.2               OCP: 18.33                                                                                                   

**Abbreviations:** BMI, body mass index; T, testosterone; M, metformin; OCP, oral contraceptive pill; TID, thrice a day; Pl, placebo; BID, twice a day; NR, not reported.

###### 

Results of selected clinical trials of metformin and oral contraceptive pills in treatment of polycystic ovary syndrome

  Trial                                    Change in mean BMI, kg/m^2^   Change in mean total C, mg/dL   Change in mean HDL-C, mg/dL    Change in mean LDL-C, mg/dL   Change in mean TG, mg/dL   Change in mean insulin, µIU/mL   Change in mean total T, ng/dL   Change in mean FT, pg/mL     Change in mean SHBG, nmol/L
  ---------------------------------------- ----------------------------- ------------------------------- ------------------------------ ----------------------------- -------------------------- -------------------------------- ------------------------------- ---------------------------- ------------------------------
  Glintborg et al[@b10-tcrm-11-1345]       M: −1.0                       NR                              NR                             NR                            NR                         M: 0.29                          M: −10.09                       NR                           M: 9
  M + OCP: −0.78                           M + OCP: −1.15                M + OCP: −12.10                 M + OCP: 106                                                                                                                                                                          
  OCP: 0.38                                OCP: 1.30                     OCP: −10.37                     OCP: 138                                                                                                                                                                              
  Essah et al[@b19-tcrm-11-1345]           M + OCP: −0.67 (*P*=0.006)    M + OCP: 8.11                   M + OCP: 4.25                  M + OCP: 2.70                 M + OCP: 47.79             M + OCP: 1.31                    M + OCP: −138.33                M + OCP: −0.05 (*P*=0.01)    M + OCP: 84.2 (*P*=0.001)
  OCP + Pl: −0.14                          OCP + Pl: 13.13 (*P*=0.03)    OCP + Pl: 2.32                  OCP + Pl: 7.34                 OCP + Pl: 38.05               OCP + Pl: −0.37            OCP + Pl: −152.73                OCP + Pl: −0.04                 OCP + Pl: 63.1               
  Panidis et al[@b20-tcrm-11-1345]         Group A: 0.01                 NR                              NR                             NR                            NR                         Group A: 4.85                    Group A: −31.01 (*P*=0.003)     NR                           Group A: 165.94 (*P*\<0.001)
  Group B: −0.02                           Group B: 2.90                 Group B: −27.55 (*P*=0.006)     Group B: 196.63 (*P*\<0.001)                                                                                                                                                          
  Group C: −1.22                           Group C: −0.93                Group C: −8.11                  Group C: 0.73                                                                                                                                                                         
  Bilgir et al[@b21-tcrm-11-1345]          M + OCP: −1.2 (*P*\<0.001)    M + OCP: −15.8 (*P*\<0.001)     M + OCP: 8.1 (*P*=0.005)       M + OCP: −7.5 (*P*\<0.001)    M + OCP: −5.1 (*P*=0.05)   M + OCP: −3.2 (*P*\<0.001)       NR                              M + OCP: −0.9 (*P*\<0.001)   NR
  OCP: −1.3 (*P*\<0.001)                   OCP: −12.0 (*P*=0.002)        OCP: 1.2                        OCP: −5.8 (*P*=0.005)          OCP: −1.8                     OCP: −2.4 (*P*\<0.001)     OCP: −0.7 (*P*\<0.001)                                                                        
  Mitkov et al[@b14-tcrm-11-1345]          M: −1.0                       M: −3.09                        M: 0.39                        NR                            NR                         NR                               M: −45                          NR                           M: 5.31 (*P*\<0.05)
  M + OCP: −0.5                            M + OCP: −12.74               M + OCP: −0.39                  M + OCP: −82                   M + OCP: 8.22                                                                                                                                          
  Morin-Papunen et al[@b12-tcrm-11-1345]   M: −0.4                       NR                              NR                             NR                            NR                         M: −2.10 (*P*\<0.05)             M: −20.17 (*P*\<0.05)           NR                           M: 4.7
  OCP: −0.2                                OCP: −1.21                    OCP: −20.17 (*P*\<0.05)         OCP: 180.4 (*P*\<0.001)                                                                                                                                                               
  Elter et al[@b22-tcrm-11-1345]           M + OCP: −0.54 (*P*=0.003)    M + OCP: 15.06                  M + OCP: 1.54                  M + OCP: −4.25                M + OCP: 1.77              M + OCP: −5.80 (*P*=0.001)       M + OCP: −32.56 (*P*=0.032)     M + OCP: −4.99 (*P*=0.001)   M + OCP: 59.71 (*P*=0.001)
  OCP: 0.25                                OCP: 22.78 (*P*=0.002)        OCP: 1.16                       OCP: 3.86                      OCP: −13.27                   OCP: −5.92                 OCP: −32.56 (*P*=0.011)          OCP: −4.11 (*P*=0.010)          OCP: 31.83 (*P*=0.003)       
  Morin-Papunen et al[@b23-tcrm-11-1345]   M: −1.2                       NR                              NR                             NR                            NR                         M: −3.84 (*P*\<0.05)             M: −20.17                       NR                           M: −5.4 (*P*\<0.05)
  OCP: −0.1                                OCP: −2.59                    OCP: −31.70 (*P*\<0.05)                                        OCP: 130.1 (*P*\<0.001)                                                                                                                                

**Abbreviations:** BMI, body mass index; total C, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TG, triglycerides; total T, total testosterone; FT, free testosterone; SHBG, sex hormone-binding globulin; M, metformin; OCP, oral contraceptive pill; NR, not reported; Pl, placebo.

###### 

Reasons for patient discontinuing selected clinical trials of metformin and oral contraceptive pills in treatment of polycystic ovary syndrome

  Trial                                    Number of patient withdrawals, n                                                  Reasons
  ---------------------------------------- --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------
  Glintborg et al[@b10-tcrm-11-1345]       M: 11                                                                             M: pregnant (n=1), wanted OCP (n=2), depression (n=1), nausea (n=1), regrets (n=4), lost to follow-up (n=2)
  M + OCP: 7                               M + OCP: nausea (n=3), regrets (n=2), lost to follow-up (n=2)                     
  OCP: 7                                   OCP: wants pregnancy (n=2), side effects (n=3), lost to follow-up (n=2)           
  Essah et al[@b19-tcrm-11-1345]           M + OCP: 2                                                                        M + OCP: lost to follow-up (n=1), moved away (n=1)
  OCP + Pl: 2                              OCP + Pl: lost to follow-up (n=1), heavy menstrual bleeding (n=1)                 
  Panidis et al[@b20-tcrm-11-1345]         Group A: 0                                                                        --
  Group B: 0                                                                                                                 
  Group C: 0                                                                                                                 
  Bilgir et al[@b21-tcrm-11-1345]          M + OCP: 0                                                                        --
  OCP: 0                                                                                                                     
  Mitkov et al[@b14-tcrm-11-1345]          M: 0                                                                              --
  M + OCP: 0                                                                                                                 
  Morin-Papunen et al[@b12-tcrm-11-1345]   M: 2                                                                              M: moved away (n=1), personal reasons (n=1)
  OCP: 1                                   OCP: headache and high blood pressure (n=1)                                       
  Elter et al[@b22-tcrm-11-1345]           M + OCP: 0                                                                        --
  OCP: 0                                                                                                                     
  Morin-Papunen et al[@b23-tcrm-11-1345]   M: 5                                                                              M: moved away (n=1), personal reasons (n=1), manifest diabetes mellitus (n=2), continuous nausea and diarrhea (n=1)
  OCP: 2                                   OCP: manifested diabetes mellitus (n=1), headache and high blood pressure (n=1)   

**Abbreviations:** M, metformin; OCP, oral contraceptive pill; Pl, placebo.
